论文部分内容阅读
目的:观察曲妥珠单抗对HER-2高表达人胃癌NCI-N87细胞株的抑制作用。方法:免疫组化法检测HER-2蛋白在NCI-N87细胞中的表达。荧光免疫杂交法(FISH)检测HER-2基因在NCI-N87细胞中的扩增情况。根据是否应用曲妥珠单抗分为对照组与药物组,其中药物组浓度分别为0.1、1、10和100μg/mL,作用72h后以CCK8法测定曲妥珠单抗对NCI-N87细胞的生长抑制作用。结果:免疫组化法检测显示,HER-2蛋白在NCI-N87细胞中的表达以细胞膜分布为主,呈棕褐色颗粒状,HER-2蛋白为可疑阳性表达(++)。荧光免疫杂交法检测显示,NCI-N87细胞HER-2/CEP17>2,存在HER-2基因扩增。CCK8实验显示,曲妥珠单抗浓度为0.1、1、10和100μg/mL时细胞存活率分别为(84.17±1.70)%、(81.21±3.94)%、(83.65±2.48)%和(80.59±4.25)%,四组间比较差异无统计学意义,P>0.05;与对照组(100%)相比,差异有统计学意义,P=0.000。结论:曲妥珠单抗对HER-2高表达人胃癌NCI-N87细胞具有一定的生长抑制作用;曲妥珠单抗浓度在0.1～100μg/mL对NCI-N87细胞的抑制作用相似。
Objective: To observe the inhibitory effect of trastuzumab on the human gastric cancer cell line NCI-N87 with high HER-2 expression. Methods: The expression of HER-2 protein in NCI-N87 cells was detected by immunohistochemistry. Fluorescence immunofluorescence (FISH) was used to detect the amplification of HER-2 gene in NCI-N87 cells. According to whether trastuzumab was divided into control group and drug group, the concentration of drug group was 0.1, 1, 10 and 100 μg / mL, respectively, and the effect of trastuzumab on NCI-N87 cells Growth inhibition. Results: Immunohistochemistry showed that the expression of HER-2 protein in NCI-N87 cells was dominated by cell membrane distribution, with brown granule shape and HER-2 protein was suspicious positive expression (++). Fluorescence immunofluorescence assay showed that there was HER-2 gene amplification in HER-2 / CEP17> 2 in NCI-N87 cells. The CCK8 assay showed that the cell viability rates were (84.17 ± 1.70)%, (81.21 ± 3.94)%, (83.65 ± 2.48)% and (80.59 ±) respectively at the concentrations of 0.1, 1, 10 and 100 μg / 4.25)% respectively. There was no significant difference among the four groups (P> 0.05). Compared with the control group (100%), the difference was statistically significant (P = 0.000). CONCLUSION: Trastuzumab can inhibit the growth of NCI-N87 cells with high expression of HER-2. The inhibitory effect of trastuzumab at concentrations of 0.1-100 μg / mL on NCI-N87 cells is similar.